MHRA: New Antidepressant Safety Measures Address Suicidal Thoughts, Sexual Dysfunction

• The MHRA has implemented new safety measures to enhance communication of suicidal thoughts and persistent sexual dysfunction risks associated with antidepressants.
• Changes include a new boxed warning in the Patient Information Leaflet, a patient card, and a future ancillary leaflet, with 'PSSD' now explicitly mentioned.
• Healthcare professionals are mandated to discuss these risks with patients upon initiation, dose changes, or review, and to report adverse reactions via the Yellow Card scheme.
• The updates follow a detailed review by a CHM Expert Working Group, addressing patient and family concerns about risk disclosure.
• Patients are advised to seek urgent medical attention for new or worsening suicidal thoughts and to consult their doctor for sexual dysfunction concerns, without stopping medication unilaterally.

The core objective of this UK drug safety update on antidepressants is to empower patients with comprehensive information, enabling more informed decisions about their treatment.

The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated comprehensive safety enhancements for all individuals undergoing antidepressant treatment in the UK. These significant changes aim to improve the clarity and effectiveness of communication regarding two critical risks: suicidal thoughts and behaviors, and persistent sexual dysfunction. This update follows a thorough review process that actively involved patients and their families, addressing long-standing concerns about the adequacy of existing information.

Key components of these new MHRA antidepressant safety measures include the introduction of a prominent boxed warning within the Patient Information Leaflet (PIL) that accompanies antidepressant medications. Additionally, a new patient card will be provided, alongside a supporting safety (ancillary) leaflet, which is slated for availability in 2027. A notable addition to the PIL for certain antidepressants is the explicit inclusion of the term "post SSRI sexual dysfunction" or PSSD, acknowledging the potential for sexual side effects to persist even after discontinuing treatment.

These updated guidelines stem from the work of a Commission on Human Medicines (CHM) Expert Working Group (EWG), which was convened specifically to evaluate the effectiveness of antidepressant risk minimization strategies. The EWG was established in response to concerns raised by patients and their families regarding the communication of risks such as suicidal ideation and sexual dysfunction, particularly when symptoms continue post-treatment. The group met between May 2024 and July 2025, with their recommendations subsequently considered by the CHM in September 2025.

Healthcare professionals are now explicitly advised to engage in detailed discussions with patients about the risk of suicidal thoughts and behaviors whenever an antidepressant is initiated, its dose is altered, or during subsequent reviews. Patients must be counselled to seek immediate medical attention if they experience new or worsening suicidal intent, especially during the initial phases of treatment or following dose adjustments. Similarly, clinicians are instructed to inform patients about the potential for sexual dysfunction, including the possibility of symptoms persisting after treatment cessation—a condition sometimes referred to as PSSD. Professionals are also expected to adhere to relevant NICE guidance, regularly monitor patients, and utilize the Yellow Card scheme for reporting any suspected adverse reactions associated with antidepressants. The ancillary leaflet, once available in 2027, will further support these crucial risk-benefit discussions.

The core objective of this UK drug safety update on antidepressants is to empower patients with comprehensive information, enabling more informed decisions about their treatment. While these risks are not new to antidepressant medications, the emphasis is on significantly improving their communication. Patients are advised that if they experience new or worsening suicidal thoughts, particularly when starting or changing doses, they should seek urgent medical attention, with resources like NHS 111, mental health crisis teams, Samaritans, or the SHOUT text service available.

Furthermore, individuals experiencing sexual dysfunction concerns, including symptoms that may continue after stopping the medicine, are encouraged to contact their healthcare professional. It is crucial for patients not to discontinue their medication without prior consultation with a healthcare provider. The new patient card and the updated antidepressant patient information leaflet are vital resources, and the forthcoming ancillary leaflet in 2027 will offer additional support, facilitating open dialogue with healthcare professionals about the benefits and risks of treatment options and safe medication use. Patients are also encouraged to contribute to drug safety by reporting any suspected side effects via the Yellow Card scheme reporting system.

Lawyers advising pharmaceutical companies or healthcare providers in the UK must review patient information materials and informed consent processes to ensure compliance with these new MHRA guidelines on antidepressant risk communication, particularly regarding suicidal ideation and persistent sexual dysfunction, to mitigate potential liability risks related to inadequate disclosure.

Source: Original reporting via government health advisory.